S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Stocks are for suckers – try this instead (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Stocks are for suckers – try this instead (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
Credit Suisse takeover hits heart of Swiss banking, identity
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Small areas reopen near Fukushima nuclear plant, few return
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Stocks are for suckers – try this instead (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Stocks are for suckers – try this instead (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
Credit Suisse takeover hits heart of Swiss banking, identity
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Small areas reopen near Fukushima nuclear plant, few return
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Stocks are for suckers – try this instead (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Stocks are for suckers – try this instead (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
Credit Suisse takeover hits heart of Swiss banking, identity
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Small areas reopen near Fukushima nuclear plant, few return
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
Stocks are for suckers – try this instead (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Stocks are for suckers – try this instead (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
Credit Suisse takeover hits heart of Swiss banking, identity
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Small areas reopen near Fukushima nuclear plant, few return
NASDAQ:NEO

NeoGenomics - NEO Stock Forecast, Price & News

$17.41
-0.20 (-1.14%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$17.29
$18.11
50-Day Range
$10.95
$19.45
52-Week Range
$6.00
$19.51
Volume
1.70 million shs
Average Volume
1.33 million shs
Market Capitalization
$2.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.89

NeoGenomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
8.5% Upside
$18.89 Price Target
Short Interest
Bearish
5.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of NeoGenomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.55) to ($0.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

939th out of 1,004 stocks

Testing Laboratories Industry

1st out of 1 stocks


NEO stock logo

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Stock News Headlines

NeoGenomics to Host Investor Day on April 4, 2023
This Tech Stock Could be the Next Amazon
You can learn its name in Luke Lango’s latest report, 5 Hypergrowth Stocks for 2023. Claim Your Free Report Here. pixel
NeoGenomics (NASDAQ:NEO) Downgraded to "Sell" at StockNews.com
Reviewing NeoGenomics (NASDAQ:NEO) and Digipath (OTCMKTS:DIGP)
This Tech Stock Could be the Next Amazon
You can learn its name in Luke Lango’s latest report, 5 Hypergrowth Stocks for 2023. Claim Your Free Report Here. pixel
NeoGenomics (NEO) Initiated with a Buy at SVB Securities
Why Shares of NeoGenomics Jumped 53.9% This Week
NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates
NeoGenomics Reports Third Quarter 2022 Results
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Company Calendar

Last Earnings
11/04/2021
Today
4/01/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$18.89
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+8.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-144,250,000.00
Pretax Margin
-31.26%

Debt

Sales & Book Value

Annual Sales
$509.73 million
Book Value
$7.90 per share

Miscellaneous

Free Float
126,183,000
Market Cap
$2.22 billion
Optionable
Optionable
Beta
1.13

Social Links


Key Executives

  • Chris Smith
    Chief Executive Officer & Director
  • Jeffrey Scott Sherman
    Chief Financial Officer
  • Steven A. Ross
    Chief Information Officer & Vice President
  • David Sholehvar
    President-Clinical Services
  • John Mooney
    Chief Technology Officer













NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price forecast for 2023?

10 brokers have issued 1-year target prices for NeoGenomics' shares. Their NEO share price forecasts range from $15.00 to $21.00. On average, they predict the company's stock price to reach $18.89 in the next year. This suggests a possible upside of 8.5% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2023?

NeoGenomics' stock was trading at $9.24 on January 1st, 2023. Since then, NEO shares have increased by 88.4% and is now trading at $17.41.
View the best growth stocks for 2023 here
.

Are investors shorting NeoGenomics?

NeoGenomics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 6,490,000 shares, an increase of 26.5% from the February 28th total of 5,130,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the days-to-cover ratio is presently 6.1 days.
View NeoGenomics' Short Interest
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) posted its earnings results on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The medical research company earned $121.30 million during the quarter, compared to the consensus estimate of $125.09 million. NeoGenomics had a negative trailing twelve-month return on equity of 9.15% and a negative net margin of 28.30%. NeoGenomics's quarterly revenue was down 3.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.04 EPS.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of -$0.38--$0.32 for the period, compared to the consensus earnings per share estimate of -$0.53. The company issued revenue guidance of $545.00 million-$555.00 million, compared to the consensus revenue estimate of $535.08 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $17.41.

How much money does NeoGenomics make?

NeoGenomics (NASDAQ:NEO) has a market capitalization of $2.22 billion and generates $509.73 million in revenue each year. The medical research company earns $-144,250,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does NeoGenomics have?

The company employs 2,100 workers across the globe.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 4/1/2023 by MarketBeat.com Staff